Comparative Pharmacology
Head-to-head clinical analysis: DETROL versus OXYBUTYNIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DETROL versus OXYBUTYNIN.
DETROL vs OXYBUTYNIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive muscarinic receptor antagonist, primarily targeting M3 receptors in the bladder, reducing detrusor muscle contractions and increasing bladder capacity.
Oxybutynin is an anticholinergic agent that competitively antagonizes muscarinic acetylcholine receptors (M1, M2, M3 subtypes) in the bladder detrusor muscle, inhibiting involuntary contractions and increasing bladder capacity.
2 mg orally twice daily; may increase to 4 mg daily in divided doses based on response.
5 mg orally 2-3 times daily; maximum 5 mg 4 times daily. Extended-release: 5-10 mg orally once daily; maximum 30 mg/day. Transdermal: 3.9 mg/day patch applied every 3-4 days. Topical gel: 1 g (3 pumps) applied once daily.
None Documented
None Documented
Clinical Note
moderateOxybutynin + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Oxybutynin."
Clinical Note
moderateOxybutynin + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Oxybutynin."
Clinical Note
moderateOxybutynin + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Oxybutynin."
Clinical Note
moderateOxybutynin + Fluconazole
Terminal half-life 6.9 hours (range 4-10 hours) for tolterodine; 7.7 hours (range 5-13 hours) for active 5-hydroxymethyl metabolite; prolonged in hepatic impairment (up to 3-fold).
Terminal half-life: 12-13 hours (range 7-20 hours) in healthy adults. In elderly, half-life may be prolonged due to reduced clearance.
Renal: 77% (as metabolites, <1% unchanged); Fecal: 17%; Biliary: minor.
Primarily hepatic metabolism; less than 1% excreted unchanged in urine. Metabolites are mainly excreted renally (50%) and fecally (40%).
Category C
Category A/B
Anticholinergic
Anticholinergic
"The metabolism of Fluconazole can be decreased when combined with Oxybutynin."